Shares of Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY - Get Free Report) saw unusually-high trading volume on Monday . Approximately 1,351,281 shares were traded during mid-day trading, an increase of 614% from the previous session's volume of 189,308 shares.The stock last traded at $26.27 and had previously closed at $26.35.
Chugai Pharmaceutical Trading Down 1.5%
The stock has a 50-day moving average price of $26.77 and a two-hundred day moving average price of $24.27. The stock has a market cap of $81.22 billion, a price-to-earnings ratio of 30.47 and a beta of 0.66.
Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last posted its earnings results on Thursday, April 24th. The company reported $0.19 earnings per share (EPS) for the quarter. The company had revenue of $1.89 billion during the quarter. Chugai Pharmaceutical had a net margin of 33.56% and a return on equity of 21.71%. Research analysts predict that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 earnings per share for the current fiscal year.
About Chugai Pharmaceutical
(
Get Free Report)
Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.
Read More
Before you consider Chugai Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chugai Pharmaceutical wasn't on the list.
While Chugai Pharmaceutical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
